Related Experiment Video
Updated: Nov 18, 2025
09:11
Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
Published on: November 23, 2019
6.9K
Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484
Machteld Sillen1, Toshio Miyata2, Douglas E Vaughan3
1Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, B-3000 Leuven, Belgium.
International Journal of Molecular Sciences
|February 5, 2021
Summary
Plasminogen activator inhibitor-1 (PAI-1) inhibitors like TM5484 bind a novel site, distinct from the presumed target. This binding mechanism reveals a new strategy for targeting PAI-1 in diseases.
Area of Science:
- Biochemistry
- Structural Biology
- Molecular Medicine
Background:
- Plasminogen activator inhibitor-1 (PAI-1) regulates fibrinolysis and is implicated in cardiovascular diseases, cancer, and fibrosis.
- PAI-1 interacts with vitronectin (Vn) and influences tissue remodeling, cell migration, and signaling.
- Small molecule inhibitors targeting PAI-1 represent a potential therapeutic strategy.
Purpose of the Study:
- To elucidate the precise binding site and mechanism of action of the PAI-1 inhibitor TM5484.
- To validate the therapeutic potential of targeting PAI-1 through structural and biochemical analysis.
Main Methods:
- X-ray crystallography was used to determine the structures of PAI-1 in complex with TM5484.
- Biochemical data were integrated with structural findings to propose an inhibition mechanism.
Main Results:
- Two X-ray crystallographic structures revealed that TM5484 binds to the flexible joint region of PAI-1, not the predicted cleft.
- This binding restricts the flexibility of the joint region, initiating a two-step inhibition process.
Conclusions:
- The flexible joint region is a novel binding site for PAI-1 inhibitors.
- TM5484's mechanism involves inducing a substrate form of PAI-1, leading to its conversion into an inert state.
- These findings offer new insights into PAI-1 inhibition and therapeutic development.
Keywords:
PAI-1 inhibitorX-ray crystallographycardiovascular diseasefibrinolysisplasminogen activator inhibitor 1thrombolysisMore Related Videos
Related Concept Videos
01:42Phosphoinositides and PIPs
9.6K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
9.6K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.3K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.3K